about
Aminooxypentane-RANTES, an inhibitor of R5 human immunodeficiency virus type 1, increases the interferon gamma to interleukin 10 ratio without impairing cellular proliferationA regulatory polymorphism in HAVCR2 modulates susceptibility to HIV-1 infectionCD4+ T cell depletion, immune activation and increased production of regulatory T cells in the thymus of HIV-infected individualsThe mucosae-associated epithelial chemokine (MEC/CCL28) modulates immunity in HIV infection.Fully immunocompetent CD8+ T lymphocytes are present in autologous haematopoietic stem cell transplantation recipients despite an ineffectual T-helper responseHiv-specific secretory IgA in breast milk of HIV-positive mothers is not associated with protection against HIV transmission among breast-fed infants.Qualitative immune modulation by interleukin-2 (IL-2) adjuvant therapy in immunological non responder HIV-infected patients.Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.CCL28 induces mucosal homing of HIV-1-specific IgA-secreting plasma cells in mice immunized with HIV-1 virus-like particlesCholecalciferol supplementation in HIV-infected youth with vitamin D insufficiency: effects on vitamin D status and T-cell phenotype: a randomized controlled trial.Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: the IMMUNEF clinical trialSpecific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trialNeurocognitive impairment in HIV-infected naïve patients with advanced disease: the role of virus and intrathecal immune activation.Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy.Retinoids, breast cancer and NK cells.Immunomodulatory activity of pidotimod administered with standard antibiotic therapy in children hospitalized for community-acquired pneumonia.Variants in the CYP7B1 gene region do not affect natural resistance to HIV-1 infection.HLA and autoimmune digestive disease: a clinically oriented review for gastroenterologists.Pseudo-mannosylated DC-SIGN ligands as potential adjuvants for HIV vaccines.High Expression of Antiviral and Vitamin D Pathway Genes Are a Natural Characteristic of a Small Cohort of HIV-1-Exposed Seronegative Individuals.In vivo imaging of immune cell trafficking in cancer.The PD-1/PD-L1 pathway in human pathology.Immune activation in africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project.A glycomimetic compound inhibits DC-SIGN-mediated HIV infection in cellular and cervical explant models.Designing nanomolar antagonists of DC-SIGN-mediated HIV infection: ligand presentation using molecular rods.Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.A 6-amino acid insertion/deletion polymorphism in the mucin domain of TIM-1 confers protections against HIV-1 infection.Identification of a Specific miRNA Profile in HIV-Exposed Seronegative Individuals.Thiazolides Elicit Anti-Viral Innate Immunity and Reduce HIV Replication.Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years.Pseudo-Mannosylated DC-SIGN Ligands as Immunomodulants.Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients.Upregulation of inflammasome activity and increased gut permeability are associated with obesity in children and adolescents.Short Communication: Immune Activation Is Present in HIV-1-Exposed Seronegative Individuals and Is Independent of Microbial Translocation.Human papilloma virus vaccination induces strong human papilloma virus specific cell-mediated immune responses in HIV-infected adolescents and young adults.A possible role for the cortisol/anticortisols imbalance in the progression of human immunodeficiency virus.Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders.Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults.Evolutionary analysis identifies an MX2 haplotype associated with natural resistance to HIV-1 infection.Restorative effect of total parenteral nutrition on natural killer cell activity in malnourished cancer patients.
P50
Q28369300-CEA98DA1-2D29-4EE3-BCFF-6B59686309ADQ28542702-E7771DDB-156F-444B-87D3-54B2CE50E581Q28751971-EEBC3F1D-18EB-42A9-B0BF-D0A818E46FEAQ33301326-37600C54-F988-43AC-B939-3F9F369FD43EQ33381644-69DF3C7B-4649-4A9A-816C-F671FB2B6B08Q33609816-72DFDA8E-77F3-476D-A154-95A2335C1A53Q33760657-FFE8E177-D1BF-473A-A998-EFFD202A0806Q33945359-036074C5-AA0E-4BA4-B5CB-A961C6016592Q34069656-90EF73B9-33FE-4FF6-921F-69CB9553D13EQ34340891-5C75601F-65BC-44D3-AF6E-3388DFCECBC9Q35074381-0DDC9B2A-80AF-483C-A87D-65EE171DB6B6Q35171253-43776E53-DC67-4A95-90A8-E072936E178CQ35872249-261F7517-8424-4BAC-A8D2-4C01AFD1E751Q35900294-4F76BB4F-B22E-4787-B5B6-7C844370DF92Q35977860-B7D22EFA-3CEA-40C9-8D58-0E0634B4875EQ36023838-0DBBFC19-BD33-4BB4-AD9E-6B55AF672CDEQ36089083-74573C10-A5F1-4A84-9027-C2CF9C6B7482Q37355718-66B4DAA1-CE49-4F7D-8F84-80979187D5ECQ37611798-0912952F-687A-41C7-8EB5-2D3187D5BA2AQ37637890-9ABB614E-424B-480B-A6A0-8E46EC40D461Q37822291-F978489F-7C01-46A1-AC76-B634BDF02010Q37980868-06A9A27B-1D3E-4A51-BE22-2F25257D7402Q38885690-8A4AB7C4-93D1-47B8-843D-78277818B5B7Q38906457-67C621A4-053C-4C30-9A2B-153F592783C7Q38913283-8A369C52-EF7B-45DE-9A17-48C3902EB5DDQ39214152-6696D0D8-A531-4C57-9B8E-04534A481552Q39367007-BEB29E4E-B686-4C15-ADF1-9DFD22F9303DQ39610476-B91CF9BA-7E92-4955-BB62-2513720D983EQ39717911-886457DD-C152-4272-A209-1BB364AE0F14Q39997616-C433363C-6BE9-4FD0-83DE-91BA21AC55F1Q40508473-8922CA33-661E-43BC-A7F3-19C6B2EAD269Q40633578-BEED9A8C-F94C-41A9-920A-C9E4B2A0A1A6Q40910105-C2E496B3-6F26-4137-8DED-CB6F18E1A3F7Q40977393-79F56893-1632-45A9-8931-CFA734E09CE0Q41350197-F6346E4C-6721-47FD-8260-1FB3ED430465Q41571935-00FA0FAC-6497-444E-B2C7-59CB2152EA92Q41932770-262ECE75-8A81-4832-91CC-D1FD5DF8727FQ42198414-6081DF3B-F669-4A04-9B2A-7FA1A851F940Q42210416-782D67B5-7241-4A2D-ADB8-46F1A662A6B1Q42514026-26F6AC3D-EBB6-4DAC-B7BA-9BFEC61CDFF2
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
итальянская биолог
@ru
հետազոտող
@hy
name
Daria Lucia Trabattoni
@ast
Daria Lucia Trabattoni
@en
Daria Lucia Trabattoni
@es
Daria Lucia Trabattoni
@nl
Daria Lucia Trabattoni
@sl
Дарья Лючия Трабаттони
@ru
type
label
Daria Lucia Trabattoni
@ast
Daria Lucia Trabattoni
@en
Daria Lucia Trabattoni
@es
Daria Lucia Trabattoni
@nl
Daria Lucia Trabattoni
@sl
Дарья Лючия Трабаттони
@ru
altLabel
Трабаттони, Дарья Лючия
@ru
prefLabel
Daria Lucia Trabattoni
@ast
Daria Lucia Trabattoni
@en
Daria Lucia Trabattoni
@es
Daria Lucia Trabattoni
@nl
Daria Lucia Trabattoni
@sl
Дарья Лючия Трабаттони
@ru
P1053
G-7424-2012
P106
P1153
7006177870
P21
P31
P3829
P496
0000-0001-9535-3359